Sign up Australia
Proactive Investors - Run By Investors For Investors

Pharmaxis secures further Australian government reimbursement for Bronchitol

Pharmaxis is a global leader in drug development for fibrosis and inflammation.
Pharmaxis secures further Australian government reimbursement for Bronchitol
The company is well-funded with $39 million in cash at the end of September

Pharmaxis Ltd (ASX:PXS) has achieved extended reimbursement of its drug Bronchitol (mannitol) on the Pharmaceutical Benefits Scheme (PBS).

This means that from the start of 2018, eligible people with cystic fibrosis who are taking Pulmozyme® (dornase alfa), another CF (cystic fibrosis) medication, will be able to add reimbursed Bronchitol to their treatment regime.

Cystic fibrosis is a genetic condition affecting one in every 2500 Australian babies.

People with the condition develop an abnormal amount of excessively thick and sticky mucus within their lungs, airways and the digestive system.

What is Bronchitol

Bronchitol has an active ingredient in mannitol, which is delivered as an inhalable dry powder to restore the airway surface liquid.

Other benefits include enhanced mucus clearance, improved lung function while reducing incidence of lung infections.

Bronchitol has been studied in more than 1000 clinical trial patients4 and is indicated for appropriate CF patients over six years of age.

Pharmaxis plans for a Bronchitol FDA re-submission by Chiesi in 2018.

Chiesi is the distributor for the major EU markets.

Importance of the listing on PBS

This new listing will allow clinicians treating cystic fibrosis to use two agents that work differently, and are proven to work together in the CF lung, to improve mucus clearance.

PBS reimbursement of this combined treatment approach will also significantly reduce paperwork for CF treating teams and improve access for patients.

Gary Phillips, chief executive officer for Pharmaxis, commented:

"We are delighted that more Australians with cystic fibrosis will now have access to treatment with Bronchitol under this expanded listing.

"We are proud that a locally developed and manufactured product is helping people living with this incurable disease."

An expanded PBS listing for Bronchitol was supported by the CF community, healthcare professionals and Cystic Fibrosis Australia in submissions to the government committee advising on medicine reimbursement.

View full PXS profile View Profile

Pharmaxis Ltd Timeline

Related Articles

January 26 2018
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said
Picture of evolis products
April 04 2018
Fillerina® is complementary to the company’s evolis® haircare range.
January 19 2018
Regulatory sign-off fires starting pistol on the commercial launch in Europe, Africa, EU Medical Devices Directive awarded CE IVD certification, molecular diagnostics, Europe, Africa, Sysmex

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use